A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Sign Up to like & getrecommendations! Published in 2017 at "Investigational New Drugs"
DOI: 10.1007/s10637-017-0467-7
Abstract: SummaryBackground Voxtalisib, a PI3K/mTOR inhibitor, has shown antitumor activity in capsule formulation in patients with solid tumors. This Phase I study assessed safety and pharmacokinetics of voxtalisib administered as immediate-release tablets in patients with solid… read more here.
Keywords: solid tumors; dose escalation; voxtalisib; safety pharmacokinetics ... See more keywords